BIND Therapeutics to Present at 26th Annual Roth Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

BIND Therapeutics, Inc. BIND, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins^TM, announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the 26^th Annual Roth Conference in Laguna Nigel, CA on Monday, March 10, 2014 at 11:30 a.m. PT.

Interested parties may access a live webcast of the presentation by visiting the BIND Therapeutics website at www.bindtherapeutics.com. The webcasts will be archived on the BIND Therapeutics website following the event for one week.

About BIND Therapeutics

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND's lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate resistant prostate cancer.

BIND has announced collaborations with Amgen, Inc., Pfizer Inc. and AstraZeneca AB to develop Accurins based on therapeutic payloads from their product pipelines. BIND's platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women's Hospital/Harvard Medical School of BIND's scientific founders and directors Dr. Robert Langer and Dr. Omid Farokhzad. For more information, please visit the company's web site at www.bindtherapeutics.com.